A Pooled Analysis of I nfections, Mal ignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel DiseaseLICHTENSTEIN, Gary R; RUTGEERTS, Paul; SANDBORN, William J et al.The American journal of gastroenterology. 2012, Vol 107, Num 7, pp 1051-1063, issn 0002-9270, 13 p.Article

Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's DiseaseTOEDTER, Gary P; BLANK, Marion; YINGHUA LANG et al.The American journal of gastroenterology. 2009, Vol 104, Num 11, pp 2768-2773, issn 0002-9270, 6 p.Article

Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosaLICHTENBERGER, Lenard M; ROMERO, Jimmy J; GIBSON, George W et al.Digestive diseases and sciences. 2000, Vol 45, Num 9, pp 1792-1801, issn 0163-2116Article

14 Day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori statusTHOMSON, Alan B. R; MARSHALL, John K; HUNT, Richard H et al.Journal of rheumatology. 2002, Vol 29, Num 9, pp 1965-1974, issn 0315-162XArticle

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseSANDBORN, William J; GASINK, Christopher; GHOSH, Subrata et al.The New England journal of medicine. 2012, Vol 367, Num 16, pp 1519-1528, issn 0028-4793, 10 p.Article

Infliximab maintenance therapy for fistulizing Crohn's diseaseSANDS, Bruce E; ANDERSON, Frank H; RACHMILEWITZ, Daniel et al.The New England journal of medicine. 2004, Vol 350, Num 9, pp 876-885, issn 0028-4793, 10 p.Article